Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

Abstract Background LUX-Lung 3 showed afatinib improved progression-free survival (PFS) compared with cisplatin plus pemetrexed in patients with epidermal growth factor receptor (EGFR) mutations. In this study, chemotherapy efficacy tended to differ between patients with Leu858Arg (L858R) point muta...

Full description

Bibliographic Details
Main Authors: Toshihiko Kaneda, Hiroshige Yoshioka, Motohiro Tamiya, Akihiro Tamiya, Akito Hata, Asukaka Okada, Takashi Niwa, Takayuki Shiroyama, Masaki Kanazu, Tadashi Ishida, Nobuyuki Katakami
Format: Article
Language:English
Published: BMC 2018-01-01
Series:BMC Cancer
Subjects:
Exon 19 deletion
L858R point mutation in exon 21
Non-squamous non-small cell lung cancer
Pemetrexed
Progression-free survival
Online Access:http://link.springer.com/article/10.1186/s12885-017-3952-7

Internet

http://link.springer.com/article/10.1186/s12885-017-3952-7

Similar Items